Ribociclib (RIBO), a first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer, is an inhibitor of CYP3A4, P-gp, and BCRP. This evidence concerns the gene ERBB2 and breast carcinoma.